Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R-CHOP-21 4 versus 6 chemotherapy cycles in young adults with low-risk aggressive CD20-positive B-cell lymphoma
2005-005217-38Phase 3Completed
- Sponsor
- German High-Grade Non-Hodgkin Lymphoma Study Group
- Start
- Jun 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone in mature B-cell lymphoma and non-Hodgkin lymphoma (NHL) (2 arms), sponsored by German High-Grade Non-Hodgkin Lymphoma Study Group. Primary endpoint: Time to treatment failure. Started Jun 2008; status: completed.
02
Drugs
rituximabcyclophosphamidedoxorubicinvincristineprednisone
03
Conditions
mature B-cell lymphomanon-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on 2005-005217-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005217-38.